Home/Pipeline/PRIMO‑TB161‑001

PRIMO‑TB161‑001

Various Solid Tumors

PreclinicalActive

Key Facts

Indication

Various Solid Tumors

Phase

Preclinical

Status

Active

Company

Primo Biotechnology

About Primo Biotechnology

Taiwan‑based radiopharmaceutical innovator delivering precision cancer diagnostics and therapeutics.

View full company profile

Therapeutic Areas

Other Various Solid Tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Guardant Infinity Biomarker Discovery	Guardant Health	Development/Commercial	Active
Cytotoxic Oncology Generic	MSN Laboratories	Pre‑clinical	Active
APCEDEN®	APAC Biotech	Approved	Commercial
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
177Lu‑BetaBart (RV‑01)	AtomVie Global Radiopharma	Phase 1/2a	Active
BeiGene Oncology Portfolio	EVA Pharma	Phase 2/3	Active
Bevacizumab Biosimilar	Bio Usawa Biotechnology	Preclinical	Active